3.97

2.22% -0.09

Orchestra Biomed Holdings Inc (OBIO)

Overview News Price History Discussions Forecast

Orchestra Biomed Holdings Inc stock is traded at $3.97, with a volume of 351.55K. It is down -2.22% in the last 24 hours and down -3.87% over the past month. Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.

Previous Close:

$4.06

Open:

$4.09

24h Volume:

351.55K

Relative Volume:

1.57

Market Cap:

$237.73M

Revenue:

$33.48M

Net Income/Loss:

$-52.70M

P/E Ratio:

-3.0801

EPS:

-1.2889

Net Cash Flow:

$-49.45M

1W Performance:

-0.75%

1M Performance:

-3.87%

6M Performance:

-24.24%

1Y Performance:

+45.96%

1-Day Range:

$3.88

$4.10

1-Week Range:

$3.88

$4.14

52-Week Range:

$2.20

$5.424

Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile

Name

Orchestra Biomed Holdings Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

646-343-9298

Address

150 UNION SQUARE DRIVE, NEW HOPE

Employee

Twitter

Next Earnings Date

2026-05-11

Latest SEC Filings

OBIO's Discussions on Twitter

Compare OBIO vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OBIO Orchestra Biomed Holdings Inc	3.97	243.12M	33.48M	-52.70M	-49.45M	-1.2889
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-25	Initiated	TD Cowen	Buy
Aug-20-25	Downgrade	BTIG Research	Buy → Neutral
Mar-20-25	Initiated	BTIG Research	Buy
Jan-02-25	Initiated	Barclays	Overweight
Aug-22-24	Initiated	H.C. Wainwright	Buy
Jul-25-24	Initiated	B. Riley Securities	Buy
Jan-19-24	Initiated	Jefferies	Buy
Feb-24-23	Initiated	Piper Sandler	Overweight
Feb-07-23	Initiated	Chardan Capital Markets	Buy

View All

Orchestra Biomed Holdings Inc Stock (OBIO) Latest News

May 25, 2026

OBIO Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline in Pre-Revenue Phase - Newser

May 25, 2026

May 22, 2026

OBIO Q1 2026 Earnings: Narrowed Loss as EPS Surpasses Estimates; Stock Posts Modest DeclineLong-Term Guidance - Newser

May 22, 2026

Orchestra BioMed Advances FDA Path for Hypertension Device - MyChesCo

May 22, 2026

Orchestra BioMed Targets 2027 Data for Hypertension Trial - MyChesCo

May 22, 2026

May 21, 2026

Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock - Yahoo Finance

May 21, 2026

May 20, 2026

Orchestra BioMed director Jason buys $2,493 in stock - Investing.com UK

May 20, 2026

Orchestra BioMed director Jason buys $2,493 in stock By Investing.com - Investing.com Canada

May 20, 2026

Orchestra BioMed (OBIO) director adds 665 shares in open-market buy - Stock Titan

May 20, 2026

Orchestra BioMed Holdings (OBIO) price target increased by 11.30% to 12.68 - MSN

May 20, 2026

May 19, 2026

Orchestra BioMed CEO David Hochman buys $18,850 in company stock By Investing.com - Investing.com Nigeria

May 19, 2026

Orchestra BioMed director Aryeh Jason buys $34,986 in stock By Investing.com - Investing.com Nigeria

May 19, 2026

Orchestra BioMed director Aryeh Jason buys $34,986 in stock - Investing.com India

May 19, 2026

Jefferies healthcare fireside chat to feature Orchestra BioMed CEO - Stock Titan

May 19, 2026

Orchestra BioMed CEO David Hochman buys $18,850 in company stock - Investing.com

May 19, 2026

Director at Orchestra BioMed (OBIO) buys 8,971 shares in open market - Stock Titan

May 19, 2026

Orchestra BioMed (OBIO) director adds 5,000 shares in open-market buy - Stock Titan

May 19, 2026

B. Riley Cuts Price Target on Orchestra BioMed Holdings to $10 From $12, Keeps Buy Rating - marketscreener.com

May 19, 2026

May 18, 2026

Orchestra BioMed director Fain buys $82,600 in shares By Investing.com - Investing.com South Africa

May 18, 2026

Orchestra BioMed director Fain buys $82,600 in shares - Investing.com UK

May 18, 2026

Orchestra BioMed (OBIO) director trust buys 20,000 shares - Stock Titan

May 18, 2026

May 17, 2026